black box warning for glp 1 agonists Thyroid Cancer: A on Anti-obesity Medications?! How does Ozempic work? The

Dehydration builds faster than people expect Reduced appetite can mean less fluid intake

K.PlutzkyJ.ArodaV

In terms of its effects, it appears to impact drinking in ways (though not necessarily mechanisms) similar to naltrexone (FDA-approved) and topiramate (prescribed off label for alcohol use disorder), which have a greater effect in reducing intensity of drinking on drinking days relative to their effects on whether someone drinks at all (i.e., abstinent days) although all of them do increase abstinent days to some degree on average)

Furthermore, on February 2025, Biocon Limited , an innovation-driven global biopharmaceutical business, has announced the launch of Liraglutide, a GLP-1 peptide for diabetes and obesity, in the United Kingdom

The REWIND trial suggested that dulaglutide might be effective for both primary and secondary cardiovascular prevention in individuals with T2DM (254)

Long-term follow-up assessments are necessary